Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covance New Signings Slow In U.S.; Kimbrell Returns To Top At Oread

Executive Summary

The discontinuation of a Lilly/Solvay cardiovascular development program in March is showing up with a six-month delay in Covance operating results with spill-over effects on the image and predictability of the CRO segment.

You may also be interested in...



Covance

Contract research organization has 175 Phase III programs ongoing, firm tells analysts Sept. 16 at the Bear Stearns health care conference in New York (1"The Pink Sheet" Sept. 13, p. 6)

Covance

Contract research organization has 175 Phase III programs ongoing, firm tells analysts Sept. 16 at the Bear Stearns health care conference in New York (1"The Pink Sheet" Sept. 13, p. 6)

Quintiles Increases Contract Win Rate But Suffers From Halt Of Antiplatelets

Quintiles has won about 550 contract bid proposals for drug development work in the U.S. during the first seven months of 1999, according to figures on its success rate provided to analysts during a Sept. 17 conference call.

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel